Cytokinetics Inc
NASDAQ:CYTK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cytokinetics Inc
NASDAQ:CYTK
|
US |
|
Parks! America Inc
OTC:PRKA
|
US |
|
N
|
Nasdaq Inc
F:NAQ
|
US |
|
Danone SA
F:BSND
|
FR |
|
T
|
T-Mobile US Inc
F:TM5
|
US |
|
N
|
Natera Inc
F:45E
|
US |
|
C
|
Chow Tai Fook Jewellery Group Ltd
XMUN:1CT
|
HK |
|
A
|
Advantest Corp
SWB:VAN
|
JP |
|
T
|
Task Group Holdings Ltd
ASX:TSK
|
NZ |
|
Coca-Cola Bottlers Japan Holdings Inc
OTC:CCOJF
|
JP |
Intrinsic Value
Is CYTK undervalued or overvalued?
See the intrinsic value estimate for Cytokinetics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Cytokinetics Does
Cytokinetics is a drug development company focused on diseases where muscles do not work properly, especially heart and skeletal muscle disorders. It designs medicines that affect the way muscle fibers contract, with a strong emphasis on treatments for heart failure and some rare neuromuscular conditions.
- Headquarters
- United States of America US
- Employees
- 673
- IPO date
- Apr 29, 2004
Cytokinetics has no economic moat
Clinicians can choose other treatments for obstructive HCM, and one patient’s use of MYQORZO does not make it more valuable to other patients. Cytokinetics has no built-in user network or customer lock-in that prevents rival medicines from competing for prescriptions.
Read the full moat analysis
Revenue & Expenses Breakdown
Cytokinetics Inc
Earnings Waterfall
Cytokinetics Inc
The intrinsic value for Cytokinetics Inc (CYTK) under the Base Case is hidden USD.
Compared with the current market price of 63.295 USD, the stock appears hidden.